Search Results - "Benton, Wade"

Five-Year Outcomes of Patients Enrolled in the REVEAL Registry by Farber, Harrison W., MD, FCCP, Miller, Dave P., MS, Poms, Abby D., BS, RRT, Badesch, David B., MD, FCCP, Frost, Adaani E., MD, Rouzic, Erwan Muros-Le, MPH, Romero, Alain J., PharmD, PhD, Benton, Wade W., PharmD, Elliott, C. Gregory, MD, McGoon, Michael D., MD, FCCP, Benza, Raymond L., MD

“…BACKGROUND Pulmonary arterial hypertension (PAH) is a rare, severe disease characterized by worsening right-sided heart failure, decreasing functional status,…”
Get full text

Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance by Farber, Harrison W., MD, Miller, Dave P., MS, McGoon, Michael D., MD, Frost, Adaani E., MD, Benton, Wade W., PharmD, Benza, Raymond L., MD

“…Background Clinical studies of pulmonary arterial hypertension have used the change in the 6-minute walk distance (6MWD) as a clinical end point; however, its…”
Get full text

Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: A Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis by Benza, Raymond L., MD, Miller, Dave P., MS, Foreman, Aimee J., MA, Frost, Adaani E., MD, Badesch, David B., MD, Benton, Wade W., PharmD, McGoon, Michael D., MD

“…Background Data from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) were used previously to develop a…”
Get full text

Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) by Preston, Ioana R, Roberts, Kari E, Miller, Dave P, Sen, Ginny P, Selej, Mona, Benton, Wade W, Hill, Nicholas S, Farber, Harrison W

“…BACKGROUND—Long-term anticoagulation is recommended in idiopathic pulmonary arterial hypertension (IPAH). In contrast, limited data support anticoagulation in…”
Get full text

Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors by Weir, Matthew R., Bushinsky, David A., Benton, Wade W., Woods, Steven D., Mayo, Martha R., Arthur, Susan P., Pitt, Bertram, Bakris, George L.

“…Older people are predisposed to hyperkalemia because of impaired renal function, comorbid conditions, and polypharmacy. Renin–angiotensin–aldosterone system…”
Get full text

Characterization of First-Time Hospitalizations in Patients With Newly Diagnosed Pulmonary Arterial Hypertension in the REVEAL Registry by Burger, Charles D, MD, Long, Pamela K, RN, Shah, Monarch R, MS, McGoon, Michael D, MD, Miller, Dave P, MS, Romero, Alain J, PharmD, PhD, Benton, Wade W, PharmD, Safford, Robert E, MD, PhD

“…BACKGROUND Hospitalization is an important outcome in pulmonary arterial hypertension (PAH), shown previously to correlate with survival. Using the Registry to…”
Get full text

The burden of hyperkalemia in patients with cardiovascular and renal disease by Dunn, Jeffrey D, Benton, Wade W, Orozco-Torrentera, Ernesto, Adamson, Robert T

“…Hyperkalemia is a potentially serious condition that can result in life-threatening cardiac arrhythmias and is associated with an increased mortality risk…”
Get full text

Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia by Li, Lingyun, Harrison, Stephen D, Cope, M Jamie, Park, Craig, Lee, Lawrence, Salaymeh, Faleh, Madsen, Deidre, Benton, Wade W, Berman, Lance, Buysse, Jerry

“…Hyperkalemia is a potentially life-threatening condition, and patients who have chronic kidney disease, who are diabetic, or who are taking…”
Get more information

Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis by Bushinsky, David A, Rossignol, Patrick, Spiegel, David M, Benton, Wade W, Yuan, Jinwei, Block, Geoffrey A, Wilcox, Christopher S, Agarwal, Rajiv

“…Persistent hyperkalemia (serum potassium (K) ≥5.5 mEq/l) is a common condition in hemodialysis (HD) patients, is associated with increased mortality, and…”
Get more information

Effect of Patiromer on Urinary Ion Excretion in Healthy Adults by Bushinsky, David A, Spiegel, David M, Gross, Coleman, Benton, Wade W, Fogli, Jeanene, Hill Gallant, Kathleen M, Du Mond, Charles, Block, Geoffrey A, Weir, Matthew R, Pitt, Bertram

“…Patiromer is a nonabsorbed potassium-binding polymer that uses calcium as the counterexchange ion. The calcium released with potassium binding has the…”
Get full text

Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease by Khanna, Dinesh, Evnin, Luke B, Assassi, Shervin, Benton, Wade W, Gordon, Gregory, Maslova, Karina, Steffgen, Juergen, Maher, Toby M

“…Safe, effective therapies are urgently needed for patients with systemic sclerosis. However, clinical trial recruitment is challenging given the limited number…”
Get full text

Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study by Frantz, Robert P., MD, Schilz, Robert J., DO, PhD, FCCP, Chakinala, Murali M., MD, FCCP, Badesch, David B., MD, FCCP, Frost, Adaani E., MD, FCCP, McLaughlin, Vallerie V., MD, FCCP, Barst, Robyn J., MD, Rosenberg, Daniel M., PhD, Miller, Dave P., MS, Hartline, Brian K., MD, Benton, Wade W., PharmD, Farber, Harrison W., MD, FCCP

“…BACKGROUND Few studies have prospectively reported outcomes in patients with pulmonary arterial hypertension (PAH) treated with epoprostenol in the modern-day…”
Get full text

Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study by Chin, Kelly M., MD, Badesch, David B., MD, Robbins, Ivan M., MD, Tapson, Victor F., MD, Palevsky, Harold I., MD, Kim, Nick H., MD, Kawut, Steven M., MD, Frost, Adaani, MD, Benton, Wade W., PharmD, Lemarie, Jean-Christophe, MSc, Bodin, Frederic, MD, Rubin, Lewis J., MD, McLaughlin, Vallerie, MD

“…Background Epoprostenol sodium with arginine-mannitol excipients (epoprostenol AM; Veletri [Actelion Pharmaceuticals Ltd, Allschwil, Switzerland]) and…”
Get full text

Qualitative Interviews to Assess the Content Validity and Usability of the Electronic Raynaud Diary in Patients with Systemic Sclerosis by Domsic, Robyn T., Pokrzywinski, Robin, Stassek, Larissa, Benton, Wade W., Vampola, Christa‐Lynn, Furst, Daniel E., Chung, Lorinda, Steen, Virginia, Mayes, Maureen D., Shah, Ami A., Molitor, Jerry A., Oliver, Kelly, Nagaraja, Vivek, Khanna, Dinesh

“…Objective To better understand the symptoms and impacts of Raynaud phenomenon (RP) in patients with systemic sclerosis (SSc) and to evaluate the content…”
Get full text

Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection by Moskowitz, Samuel M., Emerson, Julia C., McNamara, Sharon, Shell, Richard D., Orenstein, David M., Rosenbluth, Daniel, Katz, Marcia F., Ahrens, Richard, Hornick, Douglas, Joseph, Patricia M., Gibson, Ronald L., Aitken, Moira L., Benton, Wade W., Burns, Jane L.

“…Rationale In cystic fibrosis (CF), conventional antibiotic susceptibility results correlate poorly with clinical outcomes. We hypothesized that biofilm testing…”
Get full text

Response to Letter Regarding Article, “Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)” by Preston, Ioana R, Roberts, Kari E, Miller, Dave P, Sen, Ginny P, Selej, Mona, Benton, Wade W, Hill, Nicholas S, Farber, Harrison W

Get full text

Bloodstream Infection Rates in Patients With Pulmonary Arterial Hypertension Treated With Epoprostenol for Injection: A PROSPECT Registry Analysis by Frantz, Robert, MD, Chakinala, Murali, MD, Barst, Robyn, MD, Schilz, Robert, MD, Chin, Kelly, MD, Hemnes, Anna, MD, Miller, Dave, MS, Benton, Wade, PharmD, Hartline, Brian, MD, Farber, Harrison, MD

Get full text

A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost by Channick, Richard N., Frantz, Robert P., Kawut, Steven M., Palevsky, Harold, Tumuluri, Ramagopal, Sulica, Roxana, Lauto, Paula O., Benton, Wade W., de Boisblanc, Bennett

“…Pulmonary arterial hypertension (PAH) is characterized by progressive increases in pulmonary vascular resistance, leading to right heart failure and death…”
Get full text

Risk of Amputation in Severe Frostbite—A Systematic Literature Review and Meta-analysis to Evaluate Iloprost and Standard of Care by Vampola, Christa-Lynn, Fahrbach, Kyle, Huelin, Rachel, Widlitz, Allison, Christal, Kevin, Benton, Wade, Davis, Christopher

Get full text

Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers by Lesko, Lawrence J, Offman, Elliot, Brew, Christine Taylor, Garza, Dahlia, Benton, Wade, Mayo, Martha R, Romero, Alain, Du Mond, Charles, Weir, Matthew R

“…Patiromer is a potassium-binding polymer that is not systemically absorbed; however, it may bind coadministered oral drugs in the gastrointestinal tract,…”
Get more information